BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC decreased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 1.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 143,874 shares of the biotechnology company’s stock after selling 1,450 shares during the quarter. Commonwealth Equity Services LLC owned approximately 0.07% of BioCryst Pharmaceuticals worth $889,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. CWM LLC raised its stake in BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 3,772 shares during the period. Diversified Trust Co grew its position in BioCryst Pharmaceuticals by 18.0% in the 2nd quarter. Diversified Trust Co now owns 24,752 shares of the biotechnology company’s stock worth $153,000 after purchasing an additional 3,774 shares during the last quarter. ProShare Advisors LLC grew its position in BioCryst Pharmaceuticals by 9.1% in the 1st quarter. ProShare Advisors LLC now owns 48,503 shares of the biotechnology company’s stock worth $246,000 after purchasing an additional 4,041 shares during the last quarter. Signaturefd LLC grew its position in BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares during the last quarter. Finally, Inspire Investing LLC grew its position in BioCryst Pharmaceuticals by 9.7% in the 1st quarter. Inspire Investing LLC now owns 69,466 shares of the biotechnology company’s stock worth $353,000 after purchasing an additional 6,141 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analysts Set New Price Targets

BCRX has been the subject of several recent analyst reports. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a report on Tuesday, August 6th. JMP Securities increased their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $14.17.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $7.92 on Wednesday. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.88. The company has a market cap of $1.63 billion, a PE ratio of -7.47 and a beta of 1.88. The firm has a 50 day simple moving average of $7.69 and a 200 day simple moving average of $6.29.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.11. The company had revenue of $109.30 million during the quarter, compared to analysts’ expectations of $98.30 million. During the same quarter in the previous year, the company earned ($0.24) EPS. The firm’s quarterly revenue was up 34.9% compared to the same quarter last year. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.45 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Amy E. Mckee sold 8,600 shares of the stock in a transaction on Monday, June 24th. The shares were sold at an average price of $6.32, for a total transaction of $54,352.00. Following the transaction, the director now owns 27,831 shares in the company, valued at approximately $175,891.92. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 4.80% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.